Yuhong Ren

6PUBLICATIONS
7CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)Haematological tumoursPredictive and prognostic markers
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (6)

|Jul 11, 2026
The efficacy, safety, and rationale of orelabrutinib combined with obinutuzumab (O2) as a first-line systemic treatment for marginal zone lymphoma.

|Sep 24, 2025
Efficacy of Pola-R-CHP and Autologous Stem Cell Transplantation in Untreated Burkitt Lymphoma: A Case Report.

Yang Yang, Yuhong Ren, Jing Li

|Jul 29, 2025
Pola-R-CHP performed well in first-line Polarix trial-ineligible and IPI 0-1 DLBCL patients : Article type: research.

Yuhong Ren, Luya Cheng, Jingli Zhuang

|May 16, 2025
Polatuzumab Vedotin, zanubrutinib and rituximab (Pola-ZR) achieved rapid and deep response in untreated frail and elderly DLBCL.

Yuhong Ren, Hui Tan, Jingli Zhuang

|Apr 13, 2023
A Machine Learning Model to Predict Survival and Therapeutic Responses in Multiple Myeloma.

Liang Ren, Bei Xu, Jiadai Xu

|Jul 01, 2022
Identification of CXCR4 Upregulation in Diffuse Large B-Cell Lymphoma Associated with Prognostic Significance and Clinicopathological Characteristics.

Yi-An Zhang, Xue Yang, Jiamei Yao

Pageof 1

Frequent Collaborators

4 joint publications

Peng Liu

1 joint publications

Yi-An Zhang

1 joint publications

Xue Yang

1 joint publications

Jiamei Yao